Table III.
Treatment | Patients, n (%) |
---|---|
Folfirinox followed by GEM, total number of chemotherapy regimens received | |
2 | 42 (100.0) |
3 | 17 (40.5) |
4 | 3 (7.0) |
Folfirinox response at 2 months | |
Disease controlled (disease stabilization or partial response) | 28 (66.6) |
Disease progression | 12 (28.6) |
NA | 2 (4.8) |
Treatment interruption following first-line therapy | |
Patients, n (%) | 12 (28.6) |
Time to second-line therapy, months | 3.4 |
GEM response at 2 months | |
Disease controlled (disease stabilization or partial response) | 11 (26.0) |
Disease progression | 31 (74.0) |
GEM toxicity, maximum grade observed | |
1 | 5 (11.9) |
2 | 6 (14.3) |
3 | 6 (14.3) |
Treatment interruption | 1 (2.4) |
GEM, gemcitabine; NA, not available.